dnastrand
break
mainli
occur
reperfus
phase
oxygen
level
increas
reactiv
oxygen
speci
ro
peroxynitrit
form
presenc
diffus
nucleu
induc
disrupt
genet
materi
result
singl
strand
dna
nick
detect
parp
label
parchain
turn
signal
dna
repair
enzym
dna
ligas
dna
polymeras
beta
isabel
et
al
repair
parchain
degrad
overactiv
parp
deplet
nad
nicotinamid
adenin
dinucleotid
store
final
lead
reduct
atplevel
end
disastr
cell
moreov
parchain
caus
releas
aif
apoptosisinduc
factor
mitochondria
cytoplasm
aif
transloc
nucleu
initi
socal
parthanato
irrevers
result
cell
death
wang
et
al
inhibitor
parppathway
minocyclin
might
prevent
atpdeplet
might
maintain
intracellular
atpcont
minocyclin
broad
spectrum
antibiot
attribut
tetracyclin
class
bacteriostat
effect
frequent
use
treatment
acn
vulgari
lyme
diseas
moreov
neuroprotect
antiinflammatori
properti
giuliani
et
al
kim
suh
rat
model
hypotherm
cardiac
arrest
drabek
et
al
could
demonstr
minocyclin
reduc
ischemiainduc
elev
brain
drabek
et
al
effect
could
shown
liver
minocyclin
significantli
decreas
hepat
express
improv
liver
function
li
et
al
parpinhibitori
effect
minocyclin
posit
influenc
cell
apoptosi
also
reveal
studi
work
group
piglet
subject
cardiopulmonari
bypass
show
less
organ
dysfunct
hippocampu
liver
kidney
minocyclin
administ
bypass
reperfus
tao
et
al
dhein
et
al
salameh
et
al
typic
plasma
concentr
patient
receiv
minocyclin
treatment
medic
reason
rang
sakellari
et
al
ten
time
higher
report
concentr
need
suffici
parpinhibit
alano
et
al
seem
reason
consid
minocyclin
applic
cardiopulmonari
bypass
clinic
set
moment
patient
studi
corrobor
protect
effect
minocyclin
miss
anoth
tetracyclin
similar
chemic
structur
minocyclin
doxycyclin
evid
tetracyclin
deriv
also
cytoprotect
activ
accord
studi
schwartz
et
al
cytoprotect
effect
tetracyclin
deriv
exclus
confin
deriv
test
show
posit
effect
ischemiareperfus
injuri
mechan
protect
obtain
clear
propos
inhibit
mpt
mitochondri
permeabl
transit
pore
respons
improv
cell
surviv
anoth
interest
featur
doxycyclin
activ
matrix
metalloproteinas
mmp
describ
wide
rang
parpinhibitor
use
mainli
basic
research
anim
cellular
model
test
ischemia
reperfus
found
pharmaceut
effect
block
parp
howev
larg
clinic
trial
carri
among
first
parpinhibitor
describ
eighti
inhibit
parp
vitro
assay
purnel
whish
follow
year
use
experiment
model
stroke
renal
ischemia
myocardi
infarct
heart
transplant
found
case
applic
prior
cellular
injuri
led
better
outcom
examin
organ
chatterje
et
al
liaudet
et
al
fiorillo
et
al
koh
et
al
recent
studi
test
rabbit
model
cpb
yeh
et
al
author
could
demonstr
parpinhibit
result
signific
decreas
cytokin
level
consequ
reduct
ro
turn
led
less
apoptosi
cardiomyocyt
improv
contractil
function
heart
anoth
wellknown
parpinhibitor
classifi
phenanthridinon
besid
parpinhibit
activ
exhibit
also
antivir
antitumor
function
lin
et
al
liang
et
al
addit
szabo
et
al
b
andrasi
et
al
demonstr
canin
model
cpb
administr
abl
significantli
reduc
endotheli
dysfunct
mesenter
vessel
frequent
seen
cpb
moreov
improv
myocardi
contract
even
pulmonari
function
similar
profil
action
attribut
show
cardioprotect
lung
protect
properti
canin
model
cardiopulmonari
bypass
injuri
also
seem
diminish
mesenter
dysfunct
describ
work
group
szabo
et
al
anoth
studi
dhein
et
al
piglet
kg
examin
model
extracorpor
circul
found
postischem
elev
tumor
necrosi
factor
heat
shock
protein
level
well
lung
impair
significantli
reduc
pretreat
promis
result
basic
research
clinic
trial
initi
involv
patient
acut
myocardi
infarct
undergo
percutan
translumin
coronari
angioplasti
ekblad
et
al
patient
seem
decreas
inflammatori
reaction
recoveri
howev
frequent
seen
nonseri
advers
event
describ
elev
liver
enzym
nausea
vomit
increas
qtc
correct
qttime
morrow
et
al
might
reason
detail
investig
possibl
protect
effect
heart
ischemia
reperfus
continu
patient
anticanc
therapi
parpinhibitor
still
investig
ongo
studi
far
human
studi
organ
protect
cpb
might
due
unfavor
side
effect
collagenolyt
factor
first
discov
gross
lapier
investig
tadpol
lose
tail
metamorphosi
gross
lapier
factor
later
name
date
differ
mmp
discov
mmp
zincdepend
endoproteinas
involv
degrad
extracellular
matrix
cleavag
cell
surfac
receptor
regul
prolifer
cell
apoptosi
migrat
moreov
influenc
cytokin
process
exampl
activ
therebi
modul
leucocyt
recruit
inflammatori
process
van
lint
libert
varieti
cardiovascular
diseas
relat
dysfunct
mmp
develop
aortic
aneurysm
ascrib
defici
activ
plaqu
vulner
patient
angina
pectori
well
impair
wound
heal
patient
suffer
diabet
mellitu
chen
et
al
martinalonso
et
al
uccioli
et
al
wang
et
al
oppon
mmp
timp
tissu
inhibitor
metalloproteinas
four
differ
inhibitor
known
interestingli
recent
metaanalysi
thorac
aortic
aneurysm
express
relat
proteinas
analyz
found
thorac
aortic
aneurysm
bicuspid
aortic
valv
differ
express
pattern
mmp
timp
compar
aortic
aneurysm
tricuspid
aortic
valv
rabkin
sinc
mmp
also
play
role
inflamm
cytokin
product
far
seek
role
mmp
cpb
inde
detect
cpb
plasma
level
significantli
elev
reach
control
level
h
consequ
leucocyt
count
also
increas
howev
describ
patient
trial
lin
et
al
associ
bypass
time
pulmonari
dysfunct
contrast
anoth
patient
trial
show
elev
level
associ
impair
oxygen
pulmonari
dysfunct
cpb
beer
et
al
thu
may
interest
inhibit
mmp
cpb
mention
tetracyclin
potent
mmpinhibitor
minocyclin
doxycyclin
oxytetracyclin
schwartz
et
al
anim
studi
doxycyclin
effect
reduc
also
show
protect
effect
lung
damag
cpb
wang
et
al
zhang
et
al
decreas
brain
also
found
drabek
et
al
attribut
minocyclin
applic
prior
hypotherm
cardiac
arrest
rat
thu
one
could
conclud
also
might
due
mmpinhibit
minocyclin
although
studi
mmplevel
measur
anoth
mechan
propos
schwartz
et
al
demonstr
studi
hepatocyt
expos
simul
ischemia
reperfus
minocyclin
doxycyclin
inhibit
cellular
death
suppress
mpt
mmpinhibit
mmpinhibitor
examin
anim
model
approv
human
medic
treatment
thu
despit
extens
preclin
research
date
mmpinhibitor
test
clinic
trial
hold
promis
effect
medic
patient
summari
block
mmp
use
tool
organoprotect
cpb
mmpinhibitor
pipelin
effect
protect
organ
cpb
clinic
set
sinc
doxycyclin
minocyclin
oxycyclin
approv
applic
medica
cpb
would
offlabel
use
might
worth
set
clinic
trial
investig
potenti
medic
cpb
ischem
hypox
condit
lead
intracellular
acidosi
result
activ
sever
transmembran
ion
pump
aim
regain
normal
intracellular
ph
follow
membran
transport
involv
process
intracellular
acidif
activ
nhe
exchang
h
ion
na
would
increas
intracellular
ph
final
lead
undesir
increas
intracellular
sodium
addit
due
dropdown
atp
nakatpas
normal
condit
maintain
transmembran
sodium
potassium
gradient
inhibit
also
contribut
elev
sodium
level
furthermor
low
ph
activ
symport
carri
cell
buffer
excess
h
ion
lagadicgossmann
et
al
process
also
lead
accumul
intracellular
na
end
stimul
exchang
extrud
sodium
calcium
enhanc
intracellular
calcium
level
hand
known
trigger
final
induc
cellular
death
garciadorado
et
al
mammalian
heart
predomin
isoform
found
blockad
benefici
ischemia
reperfus
injuri
demonstr
langendorff
heart
prepar
inhibit
cariporid
led
signific
fewer
alter
cardiac
hemodynam
lower
incid
ventricular
fibril
less
pronounc
decreas
intracellular
atp
dhein
et
al
work
group
could
also
show
intracellular
acidif
isol
guinea
pig
myocardi
cell
result
signific
increas
sodium
even
pronounc
contain
tyrod
solut
salameh
et
al
cariporid
prevent
increas
sodium
quit
effici
surprisingli
rise
intracellular
calcium
seen
specul
due
inhibitori
effect
h
ion
exchang
doer
et
al
thu
inhibit
seem
favor
tool
protect
myocardium
ischem
process
inde
sever
anim
studi
simul
cpb
proven
cariporid
kindr
zoniporid
effect
cardiac
protect
addit
led
improv
neurolog
outcom
clementsjeweri
et
al
liakopoulo
et
al
moreov
model
orthotop
heart
transplant
cariporid
led
better
ventricular
recoveri
martin
et
al
anoth
studi
group
came
conclus
heart
transplant
experi
could
demonstr
cariporid
significantli
better
preserv
donor
heart
lower
level
troponin
compar
control
group
without
cariporid
ryan
et
al
howev
posit
result
nheinhibit
ischem
heart
could
transfer
organ
studi
pig
undergo
cpb
improv
disturb
lung
function
seen
experiment
group
receiv
cariporid
even
wors
compar
control
group
eichler
et
al
one
may
assum
organ
nhe
may
miss
subtyp
nhe
may
express
guardian
trial
nearli
patient
undergo
coronari
arteri
bypass
surgeri
cariporid
highest
dose
mg
led
signific
reduct
death
myocardi
infarct
theroux
et
al
dose
test
mg
benefici
effect
neither
death
myocardi
infarct
subsequ
studi
scholz
et
al
high
risk
patient
guardian
studi
popul
includ
either
receiv
mg
cariporid
respect
blood
sampl
taken
prior
coronari
arteri
bypass
oper
h
surgeri
serum
level
measur
protein
found
excel
marker
neuron
damag
elev
plasma
level
posit
correl
neuropatholog
condit
zongo
et
al
scholz
cowork
demonstr
cpb
elev
serum
concentr
sixfold
preoper
statu
cariporid
three
dose
effect
significantli
lower
level
highest
dose
nearli
preoper
level
howev
overal
postop
outcom
influenc
probabl
partial
due
small
number
patient
per
group
power
station
essenti
cell
surviv
sinc
produc
global
energi
supplier
atp
via
respiratori
chain
sever
pathophysiolog
process
traumata
ischemia
neurodegener
reyesyndrom
mitochondria
might
damag
undergo
transit
permeabl
mean
mitochondria
lose
imperm
open
socal
permeabl
transit
pore
mptp
lemast
et
al
pore
first
discov
hunter
et
al
describ
process
induc
calcium
ion
permeabl
inner
mitochondri
membran
increas
result
mitochondri
swell
loss
transmembran
potenti
atp
aifreleas
final
cell
death
factor
induc
mpt
free
radic
fatti
acid
inorgan
phosphat
nichol
brand
garciaruiz
et
al
honda
ping
howev
calcium
ion
seem
import
open
mptp
regard
heart
myocardi
infarct
intracellular
calcium
ion
rise
induc
calcium
overload
hypercontract
cardiac
cell
cell
death
garciadorado
et
al
thu
block
mptp
might
use
tool
inhibit
deleteri
effect
permeabl
transit
small
trial
piot
et
al
describ
reduc
infarct
size
patient
acut
myocardi
infarct
treat
cyclosporin
pci
howev
larger
trial
confirm
result
avail
recent
publish
patient
trial
hausenloy
et
al
report
reduc
troponin
level
patient
undergo
cpb
treat
cyclosporin
prior
bypass
especi
high
risk
patient
longer
clamp
time
cyclosporin
treatment
seem
advantag
moreov
sever
anim
studi
suggest
addit
cyclosporin
cardiopleg
solut
benefici
heart
protect
sens
heart
treat
cyclosporin
recov
faster
lower
malondialdehyd
level
lower
level
proapoptot
factor
less
mitochondri
alter
oka
et
al
pritzwaldstegmann
et
al
anoth
promis
mptinhibitor
aminoacidlik
substanc
taurin
acid
taurin
typic
found
high
concentr
cardiac
skelet
muscl
retina
central
nervou
system
posit
biolog
action
ascrib
taurin
antiarrhythm
activ
posit
inotrop
function
antioxid
properti
prevent
myocardi
calcium
overload
occur
ischemiareperfus
injuri
inhibit
mitochondri
swell
prevent
mptp
open
ueno
et
al
chen
et
al
thu
administr
taurin
might
use
possibl
minim
cardiac
damag
cpb
schaffer
et
al
patient
trial
milei
et
al
patient
six
receiv
taurin
prior
surgeri
bypass
vs
six
without
found
cardiac
biopsi
taurin
supplement
heart
exhibit
less
lipid
peroxid
format
less
mitochondri
damag
henc
less
necrot
myocardi
cell
could
also
verifi
sever
anim
studi
oriyanhan
et
al
sahin
et
al
addit
ueno
et
al
demonstr
biochem
paramet
significantli
lower
ie
creatin
kinas
lipid
peroxid
heart
treat
taurin
also
heart
function
significantli
improv
ie
left
ventricular
systol
diastol
pressur
rate
pressur
increas
decreas
thu
taurin
applic
might
benefici
cardiac
surgeri
larger
clinic
trial
evalu
protect
potenti
taurin
miss
similarli
data
taurin
effect
cpb
organ
like
brain
lung
kidney
avail
mention
tetracyclin
deriv
minocyclin
abil
inhibit
calciuminduc
mitochondri
swell
ischemiareperfus
anim
model
orthotop
liver
transplant
theruvath
et
al
demonstr
effect
blockad
mpt
minocyclin
cyclosporin
tetracyclin
mechan
propos
inhibit
calciuminduc
mpt
open
mitochondri
swell
depolar
led
collaps
oxid
phosphoryl
cell
necrosi
howev
particular
sideeffect
minocyclin
seem
cell
type
depend
also
depend
appli
minocyclin
concentr
mitochondria
brain
spinal
cord
minocyclin
significantli
inhibit
mitochondri
swell
calciumuptak
high
dose
wherea
lower
concentr
almost
increas
swell
respons
elev
calcium
level
mansson
et
al
thu
exact
mechan
minocyclin
exert
protect
effect
still
need
unravel
ro
ie
peroxid
superoxid
hydroxyl
radic
physiolog
form
oxid
phosphoryl
within
mitochondria
usual
cell
capabl
protect
neutral
endogen
ro
howev
oxid
stress
overwhelm
cellular
protect
mechan
initi
apoptosi
may
result
zakkar
et
al
cpb
one
known
exogen
factor
caus
inflamm
oxid
stress
wide
accept
oxygen
radic
signific
neg
impact
cell
integr
ischemia
reperfus
thu
antioxid
addit
might
help
cpb
one
ebselen
selen
deriv
found
significantli
improv
neurolog
outcom
stroke
patient
ebselen
appli
earli
onset
stroke
yamaguchi
et
al
piglet
bypass
model
min
aortic
clamp
chen
et
al
test
effect
ebselen
cardiac
protect
found
addit
ebselen
cardiopleg
solut
led
significantli
improv
cardiac
recoveri
less
cardiomyocyt
apoptosi
better
preserv
mitochondri
morpholog
similar
result
report
cabiga
et
al
studi
isol
rabbit
heart
perfus
accord
langendorff
anoth
interest
famili
drug
antioxid
ingredi
black
green
tea
green
tea
possess
higher
antioxid
properti
black
tea
vivo
studi
man
serafini
et
al
could
demonstr
ingest
green
tea
blood
antioxid
capac
increas
min
gallat
epigallocatechin
egcg
main
ingredi
green
test
variou
experiment
set
inflamm
cancer
ischemia
rat
model
myocardi
infarct
egcg
success
reduc
infarct
size
block
nuclear
transloc
transcript
factor
aneja
et
al
factor
neg
associ
myocardi
injuri
moreov
work
group
could
show
piglet
model
egcg
significantli
reduc
kidney
damag
earli
marker
apoptosi
cpb
twal
et
al
experi
reveal
cpb
caus
signific
swell
bowman
glomeruli
vacuol
tubul
loss
energi
rich
phosphat
rise
creatinin
urea
increas
factor
cellular
damag
deleteri
effect
cpb
could
prevent
egcg
model
neuroprotect
potenc
egcg
also
test
could
prove
hippocamp
impair
less
experiment
group
treat
egcg
salameh
et
al
howev
larger
human
trial
requir
establish
safeti
effect
egcg
nacetyllcystein
nac
wide
use
medica
treatment
chronic
obstruct
lung
diseas
cystic
fibrosi
paracetamol
intox
nac
might
act
scaveng
oxygen
radic
known
antioxid
properti
seem
obviou
test
drug
ischemia
reperfus
injuri
recent
studi
dog
qu
et
al
could
show
cpb
accompani
sever
lung
alter
alveolar
congest
neutrophil
infiltr
thicken
alveolar
wall
well
decreas
oxygen
index
elev
malondialdehyd
concentr
decreas
superoxid
dismutas
activ
studi
nac
reduc
morpholog
biochem
paramet
control
level
improv
lung
function
small
patient
trial
eren
et
al
report
reduc
mda
level
lower
alveolararteri
oxygen
gradient
group
treat
nac
howev
lung
paramet
lung
complianc
shunt
flow
pulmonari
vascular
resist
wedg
pressur
differ
two
patient
group
without
nac
likewis
signific
differ
clinic
outcom
patient
anoth
prospect
random
placebocontrol
studi
includ
patient
chronic
kidney
diseas
undergo
cpb
nac
appli
maxim
dose
start
h
bypass
trial
reveal
nac
receiv
group
ngal
neutrophil
gelatinaseassoci
lipocalin
marker
acut
kidney
injuri
ro
level
lower
compar
control
group
without
nac
addit
signific
lower
incid
acut
renal
failur
nacreceiv
group
describ
santanasanto
et
al
howev
trial
nac
fail
show
protect
effect
kidney
naughton
et
al
patient
trial
posit
effect
nac
myocardi
oxid
stress
also
demonstr
howev
signific
improv
clinic
outcom
proven
et
al
kurian
paddikkala
atpsensit
potassium
channel
ikatp
first
discov
cardiac
cell
noma
describ
outward
current
decreas
intracellular
atp
channel
found
plasma
membran
sarcolemma
mitochondria
nuclei
sever
cell
type
ie
cardiac
cell
smooth
muscl
cell
pancrea
betacel
neuron
tinker
et
al
heart
activ
ikatp
caus
shorten
action
potenti
therebi
shorten
open
state
ical
thu
prevent
calcium
overload
myocardi
cell
calcium
overload
occur
ischemia
contribut
cardiomyocyt
damag
apoptosi
ikatp
open
could
exert
protect
effect
ischemia
reperfus
injuri
moreov
increas
k
conduct
may
also
lead
hyperpolar
vascular
smooth
muscl
cell
vasodilat
coronari
peripher
arteri
consequ
peripher
resist
would
decreas
coronari
reserv
would
increas
final
may
facilit
cardiac
blood
suppli
hemodynam
larg
random
doubl
blind
placebo
control
trial
patient
angina
pectori
ikatp
open
nicorandil
show
signific
improv
outcom
less
myocardi
infarct
nicorandil
group
iona
studi
group
moreov
found
anim
studi
pig
nicorandil
use
togeth
cold
blood
cardiopleg
solut
preserv
myocardi
function
better
cold
hyperkalem
crystalloid
hyperkalem
blood
cardioplegia
steensrud
et
al
patient
trial
nicorandil
administ
cpb
reveal
patient
nicorandil
group
shorter
time
electromechn
arrest
administr
cardioplegia
lower
troponin
level
less
arrhythmia
chinnan
et
al
yamamoto
et
al
howev
larger
trial
confirm
result
miss
ikatp
open
like
aprikalim
test
myocardi
cell
cultur
shown
addit
aprikalim
cardiopleg
arrest
cultur
cell
improv
cardiomyocyt
contractil
function
led
less
calcium
overload
dorman
et
al
moreov
studi
piglet
diazoxid
select
mitochondri
ikatp
open
preserv
mitochondri
function
morpholog
cardiopleg
arrest
compar
control
heart
measur
author
conclud
preserv
mitochondri
function
contribut
improv
myocardi
function
cpb
diazoxid
group
wang
et
al
contrast
ikatp
open
ikatp
blocker
pursu
differ
strategi
ischemia
reperfus
block
atpsensit
potassium
channel
prevent
potassium
efflux
follow
atpdeclin
result
decreas
action
potenti
durat
spatial
dispers
repolar
electrophysiolog
inhomogen
promot
develop
reentrant
arrhythmia
wild
ikatp
blocker
like
antidiabet
drug
glibenclamid
cardiac
specif
ikatp
blocker
found
effect
inhibit
ventricular
tachycardia
myocardi
infarct
anim
model
dhein
et
al
wirth
et
al
howev
cpb
clinic
set
ikatp
blocker
test
far
sever
pharmacolog
addit
tri
clinic
set
minim
organ
dysfunct
cpb
blocker
esmolol
class
ii
antiarrhythm
drug
develop
treat
supraventricular
tachycardia
intraven
applic
esmolol
short
halflif
min
rapidli
hydrolyz
plasma
esteras
make
drug
well
manag
esmolol
use
cpb
children
demonstr
patient
esmolol
group
lower
creatin
kinas
troponin
lactat
level
less
need
inotrop
support
moreov
myocardi
structur
better
preserv
kuhnregni
et
al
gui
et
al
idea
anoth
studi
group
use
antioxid
properti
vitamin
e
c
cpb
small
patient
trial
patient
show
cpbcaus
oxid
stress
lower
vitamin
treat
group
howev
whether
accompani
signific
better
clinic
outcom
could
proven
barta
et
al
recent
studi
weak
benefici
effect
vitamin
e
c
applic
cpb
found
signific
posit
effect
patient
outcom
appar
gune
et
al
may
suggest
posit
effect
vitamin
partial
depend
preexist
vitamin
deficit
anoth
antioxid
use
makhija
et
al
prospect
random
trial
patient
undergo
coronari
arteri
bypass
surgeri
pretreat
day
clinic
outcom
evalu
result
reveal
treat
group
patient
less
arrhythmia
lower
need
inotrop
support
shorter
inhospit
stay
thu
seem
may
exert
certain
benefici
effect
patient
outcom
similar
result
found
earlier
sunamori
et
al
also
demonstr
effect
preserv
left
ventricular
function
reduc
left
ventricular
injuri
howev
exact
biochem
mechan
underli
protect
heart
remain
elucid
recent
studi
publish
applic
polyunsatur
fatti
acid
given
prior
bypass
oper
veljov
et
al
result
patient
trial
follow
patient
treatment
group
lower
troponin
creatin
kinas
level
higher
oxygen
extract
compar
control
group
accordingli
conclud
studi
group
polyunsatur
fatti
acid
might
use
addit
cardiac
oper
cpb
induc
system
inflammatori
reaction
thu
obviou
idea
suppress
inflamm
applic
corticosteroid
mcbride
et
al
show
small
patient
trial
subclin
renal
injuri
diminish
patient
group
receiv
methylprednisolon
although
renal
dysfunct
could
prevent
anoth
studi
involv
neonat
undergo
arteri
switch
oper
dexamethason
appli
cpb
level
inflammatori
molecul
measur
myocardi
tissu
hey
et
al
result
trial
favor
dexamethason
group
certain
myocardi
protect
seen
lower
troponin
level
less
requir
catecholamin
recent
publish
comprehens
review
kristel
et
al
advantag
disadvantag
corticosteroid
discuss
evalu
result
sever
studi
found
corticosteroid
significantli
decreas
incid
atrial
fibril
appli
low
dose
also
reduc
interv
mechan
ventil
contrast
higher
dose
corticosteroid
neg
impact
durat
intub
myocardi
infarct
stroke
renal
failur
mortal
significantli
diminish
corticosteroid
sinc
possibl
side
effect
corticosteroid
hyperglycemia
infect
disturb
wound
heal
gastrointestin
bleed
need
taken
account
routin
applic
substanc
recommend
present
studi
requir
evalu
potenti
posit
effect
corticosteroid
heart
protect
cpb
alway
matter
debat
heart
perfus
cardiopulmonari
arrest
mean
cardiac
muscl
period
absolut
ischemia
surviv
myocardi
tissu
surfac
cool
essenti
one
hand
induct
cardioplegia
hand
previou
describ
manipul
aim
protect
heart
peripher
organ
chang
cardiopleg
solut
primarili
design
organ
protect
heart
achiev
cold
cardiopleg
arrest
heart
sever
cardiopleg
solut
use
best
known
extracellular
st
thoma
hospit
mixtur
high
potassium
magnesium
bretschneid
cardiopleg
solut
socal
intracellular
solut
low
sodium
calcium
high
potassium
crystalloid
solut
use
cold
cardiopleg
arrest
braimbridg
et
al
bretschneid
third
one
name
calafior
blood
cardioplegia
also
clinic
use
cpb
oxygen
blood
supplement
high
potassium
magnesium
administ
via
aortic
root
cardiac
arrest
calafiori
cowork
describ
advantag
warm
blood
cardioplegia
versu
cold
blood
cardioplegia
sens
myocardium
specif
enzym
lower
postop
outcom
patient
better
group
receiv
warm
blood
cardioplegia
calafior
et
al
author
obtain
differ
result
subsequ
trial
cold
warm
cardiopleg
arrest
et
al
found
slightli
better
outcom
patient
cold
cardioplegia
particular
patient
long
clamp
time
howev
number
patient
studi
quit
small
patient
group
versu
patient
studi
calafior
et
al
gener
state
question
kind
cardioplegia
cold
warm
blood
crystalloid
best
specif
heart
oper
resolv
nevertheless
sever
addit
tri
minim
ischemiareperfus
injuri
better
preserv
energi
balanc
heart
dog
model
hypotherm
cardiac
arrest
bretschneid
cardiopleg
solut
custodiol
supplement
larginin
deferoxamin
iron
chelat
custodioln
demonstr
atpcont
significantli
higher
level
myeloperoxidas
marker
leucocyt
activ
inflamm
significantli
lower
custodioln
group
vere
et
al
moreov
new
custodioln
solut
also
show
protect
effect
improv
myocardi
function
rat
model
heterotop
heart
transplant
howev
addit
iron
chelat
desferoxamin
tend
neg
impact
heart
protect
koch
et
al
model
fail
heart
undergo
cpb
new
bretschneid
solut
develop
preserv
energi
level
myocardi
cell
enrich
amino
acid
iron
chelat
ketoglutar
saccharos
solut
also
exhibit
protect
influenc
atplevel
cardiac
function
improv
cardiac
stroke
volum
work
trescher
et
al
howev
none
substanc
administ
clinic
set
publish
control
patient
trial
effect
side
effect
avail
moreov
cardiac
effect
addit
studi
extens
possibl
organ
protect
drug
organ
brain
lung
kidney
liver
gut
often
investig
decad
ago
organ
protect
effect
cpb
mainli
aim
cardioprotect
recent
year
deleteri
effect
cpb
organ
kidney
brain
lung
liver
becam
center
interest
thu
initi
decad
scientist
surgeon
experi
vari
cardiopleg
solut
protocol
includ
pulsatil
flow
protocol
hypotherm
arrest
warm
blood
cardioplegia
recent
protect
brain
kidney
lung
liver
becam
target
new
strategi
often
aim
biochem
process
activ
ischemiareperfus
injuri
associ
cpb
thu
shown
cpb
acut
induc
ischemiareperfus
injuri
kidney
lung
brain
differ
target
parpinhibit
mptpinhibit
nhe
blockad
antioxid
antiapoptot
strategi
still
mani
promis
substanc
posit
test
ischemiareperfus
protocol
remain
evalu
clinic
clinicallik
cpbsetup
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
